Ayurcann Granted R&D License

NEWS RELEASE
AYURCANN GRANTED R&D LICENSE
FOR IMMEDIATE RELEASE, September 18th, 2019

Pickering, Ontario, September 18th, 2019 – Ayurcann Inc. operating as XTRX Solutions (“XTRX” and/or “Company”), is pleased to announce that the Company has been issued a cannabis Research and  Development (“R&D”) license by Health Canada on August 23, 2019.

XTRX’s new cannabis R&D license is effective immediately and will allow the company to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The Company is now able to conduct proprietary optimization studies for CO2 and Ethanol extraction processes and evaluate how to produce best in class products into the medical and recreational markets. With Cannabis 2.0 becoming available in October 2019, topical and orally-ingested consumables are going to become the new industry norm. XTRX is working with industry partners to enhance the delivery methods and performance characteristics of active ingredients including THC, CBD, and other molecules of interest. “This license will greatly enhance our ability to work with Licensed Producers to perform in-house work on customized formulations that could benefit each of Canada’s licensed cannabis companies” said Roman Buzaker, Co-Founder of XTRX.

About XTRX Solutions.

XTRX Solutions mission is to be the leading provider of customized post-harvest outsourcing solutions to licensed cannabis producers. We offer end-to-end full outsource solutions to clients which include Extraction & Refinement, Formulation & Packaging, Fulfillment & Distribution. A customer LP is able to focus on their genetics, cultivation and harvesting operations and outsource all of the rest to XTRX Solutions. For more information please visit www.xtrx.ca.

For further information please contact:
Natalie Dolphin
Director of Business Development
XTRX Solutions
T: (905) 492-3322 x 311
E: natalie@xtrx.ca

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release. Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the future plans, objectives or goals, including words to the effect that the company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

Subscribe to our newsletter to stay up-to-date with Ayurcann.